Emergent Biosolutions, Inc. (EBS) Social Stream
EMERGENT BIOSOLUTIONS INC (EBS) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering EMERGENT BIOSOLUTIONS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-08 | 7 | $120 | $50 | $83.666 | $12.19 | 586.35% |
| 2021-11-10 | 7 | $120 | $50 | $80 | $12.19 | 556.28% |
| 2022-01-18 | 6 | $75 | $50 | $62.5 | $12.19 | 412.72% |
| 2022-02-25 | 6 | $77 | $55 | $66.4 | $12.19 | 444.71% |
| 2022-02-28 | 6 | $77 | $40 | $61 | $12.19 | 400.41% |
| 2022-03-09 | 6 | $77 | $40 | $60.8 | $12.19 | 398.77% |
| 2022-04-27 | 6 | $77 | $40 | $60.6 | $12.19 | 397.13% |
| 2022-05-02 | 6 | $77 | $30 | $56.6 | $12.19 | 364.32% |
| 2022-05-03 | 6 | $77 | $30 | $50.2 | $12.19 | 311.81% |
| 2022-05-04 | 6 | $77 | $30 | $48.166 | $12.19 | 295.13% |
| 2022-05-10 | 5 | $77 | $30 | $48.166 | $12.19 | 295.13% |
| 2022-06-06 | 5 | $66 | $30 | $46.333 | $12.19 | 280.09% |
| 2022-08-03 | 5 | $65 | $30 | $43 | $12.19 | 252.75% |
| 2022-09-13 | 5 | $65 | $29 | $42.833 | $12.19 | 251.38% |
| 2022-10-26 | 5 | $65 | $29 | $42.666 | $12.19 | 250.01% |
| 2022-11-09 | 5 | $55 | $25 | $40.333 | $12.19 | 230.87% |
| 2022-11-11 | 5 | $55 | $23 | $36.5 | $12.19 | 199.43% |
The Trend in the Analyst Price Target
Over the past 30 months, EBS's average price target has gone down $45.33.
EBS reports an average of 68.09% for its upside potential over the past 42 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-02-17 | 6 | 77 | 55 | 66.400 | 42.46 | 56.38% |
| 2022-05-02 | 6 | 77 | 30 | 56.600 | 33.78 | 67.55% |
| 2022-06-06 | 4 | 65 | 30 | 44.500 | 30.80 | 44.48% |
| 2022-08-03 | 5 | 65 | 30 | 43.000 | 30.72 | 39.97% |
| 2022-09-13 | 5 | 65 | 29 | 42.833 | 22.87 | 87.29% |
EBS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.6 | 1 | 0 | 4 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
EBS's average broker recommendation rating worsened by 0.33 over the prior 153 days.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- EBS has a greater upside potential (average analyst target price relative to current price) than 1838.22% of all US stocks.
- In terms of how EMERGENT BIOSOLUTIONS INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -1508.22% of that group.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, EMERGENT BIOSOLUTIONS INC's average analyst price target is higher than 1495.41% of them.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, EMERGENT BIOSOLUTIONS INC's number of analysts covering the stock is greater than 670.72% of them.
In the Pharmaceutical Products industry, SUPN, PBH, and ICPT are the three stocks most similar to EMERGENT BIOSOLUTIONS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for EBS? Use POWR Ratings for clearer insight into price direction.